Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Clearmind Medicine Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
CMND
Nasdaq
2830
www.clearmindmedicine.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Clearmind Medicine Inc.
SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico
- Feb 4th, 2025 2:00 pm
Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico
- Feb 4th, 2025 1:35 pm
Clearmind Medicine Announces Shareholders Meeting Results
- Jan 7th, 2025 2:28 pm
Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
- Jan 6th, 2025 1:15 pm
SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
- Jan 6th, 2025 12:50 pm
Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office
- Jan 2nd, 2025 12:45 pm
Clearmind Medicine to move forward with MEAI-based alcohol substitute
- Dec 27th, 2024 12:05 pm
Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute
- Dec 26th, 2024 11:59 am
Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial
- Dec 24th, 2024 11:55 am
Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format
- Dec 16th, 2024 1:37 pm
Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
- Oct 10th, 2024 12:07 pm
Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy
- Sep 16th, 2024 8:06 pm
Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
- Sep 12th, 2024 12:20 pm
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
- Sep 6th, 2024 11:55 am
Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
- Sep 6th, 2024 11:55 am
Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
- Aug 29th, 2024 8:25 pm
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
- Aug 25th, 2024 1:54 pm
Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment
- Aug 21st, 2024 8:11 pm
Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
- Aug 16th, 2024 8:14 pm
SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
- Aug 6th, 2024 12:57 pm
Scroll